Top

American Journal of Clinical Dermatology

Published in:

01-12-2012 | Case Reports

Lichen Planus-Like Drug Eruptions Due to β-Blockers

A Case Report and Literature Review

Authors: Dr Chris Fessa, Penny Lim, Steve Kossard, Shawn Richards, Pablo Fernandez Peñas

Published in: American Journal of Clinical Dermatology | Issue 6/2012

Abstract

Lichen planus-like drug eruptions (LDE) can appear similar or identical to idiopathic lichen planus. We present a 45-year-old man with a widespread, violaceous, papular, generalized exanthema with histologic features of a lichenoid reaction, which subsequently resolved with the cessation of labetatol. We found 29 cases of previously reported β-adrenoceptor antagonist (β-blocker)-associated LDE. This is a relatively rare complication that may present as classic lichenoid papules indistinguishable from lichen planus and has a predilection for the limbs, chest, back, and oral mucosa. Histologically, there is a lichenoid infiltrate often with eosinophils. LDE may be due to drug cross-reactivity or as a result of a suppressed skin adrenergic system. Multiple potential medications in case studies and the inability to differentiate LDE from idiopathic lichen planus in cross-sectional association studies make any conclusive analysis difficult.

Richards S. Cutaneous side-effects of beta-adrenergic blockers. Aust J Derm 1985; 26: 25–8CrossRef

Belrani VS. Cutaneous manifestations of adverse drug reactions. Immunol Allergy Clin North Am 1998; 18: 867–95CrossRef

Upadhayai JB, Nangia AK, Mukhija RD, et al. Cutaneous reactions due to antihypertensive drugs. Indian J Dermatol 2006; 51: 189–91CrossRef

Abraham J, Davis C. Testing times: the emergence of the practolol disaster and its challenge to British drug regulation in the modern period. Soc Hist Med 2006; 19: 127–47PubMedCrossRef

Kaomongkolgit R. Oral lichenoid drug reaction associated with anti-hypertensive and hypoglycaemic drugs. J Drugs Dermatol 2010; 9: 73–5PubMed

Oliver FG, Winkelmann RK, Muller SA. Lichenoid dermatitis: a clinicopathologic and immunopathologic review of sixty-two cases. J Am Acad Dermatol 1989; 21: 284–92PubMedCrossRef

Van der Haute V, Lachapelle AJM. Histopathological discriminant criteria between lichenoid drug eruption and idiopathic lichen planus: retrospective study on selected samples. Dermatologica 1989; 179: 10–3PubMedCrossRef

Hawk JLM. Lichenoid drug eruption induced by propanolol. Clin Exp Dermatol 1980; 5: 93–6PubMedCrossRef

Massa MC, Jason SM, Gradini R, et al. Lichenoid drug eruption secondary to propranolol. Cutis 1991; 48: 41–3PubMed

10.

Finlay AY, Waddington E, Savage RL. Cutaneous reactions to labetalol. BMJ 1987; 1 (6118): 987

11.

Gange RW, Jones EW. Bullous lichen planus caused by labetalol. BMJ 1978; 1(6116): 816–7PubMedCrossRef

12.

Staughton R, Sutton R, Farrell M. β-Blockers, autoimmunity and rashes. Lancet 1980; 2(8194): 581PubMedCrossRef

13.

Beckman KA, Chanes L, Kaufman SR. Lichen planus associated with topical beta-blocker therapy. Am J Ophthalmol 1995; 4: 530–1

14.

Meyer S, Burgdorff SM, Szeimies TV, et al. Management of erosive lichen planus with topical tacrolimus and recurrence secondary to metoprolol. JEADV 2005; 19: 236–9PubMed

15.

O’Brien TJ, Lyall IG, Reid SS. Lichenoid eruption induced by sotalol. Australas J Dermatol 1994; 35: 93–4PubMedCrossRef

16.

Taylor AE, Hindson C, Wacks H. A drug eruption due to acebutolol with combined lichenoid and lupus erythematous features. Clin Exp Dermatol 1982; 7: 219–21PubMedCrossRef

17.

Mullins RJ, Lones R, Dutta Lichenoid drug eruption secondary to topical timolol and dorzolamide eye-drops. Australas J Dermatol 2004; 45: 151–2PubMedCrossRef

18.

Bodmer M, Egger SS, Hohenstein E, et al. Lichenoid eruption associated with the use of nebivolol. Ann Pharmacother 2006; 40(9): 1688–90PubMedCrossRef

19.

Wiesenfeld D, Scully MacFadyen Multiple lichenoid drug reactions in a patient with Ferguson-Smith disease. Oral Surg Oral Med Oral Pathol 1982; 54: 527–9PubMedCrossRef

20.

Ruiz VR, Blasco MJ, Mendoza GF, et al. Generalized lichen planus-like eruption due to acetylsalicylic acid. J Eur Acad Dermatol Venereol 2003; 17: 470–2CrossRef

21.

Firth NA, Reade PC. Angiotensin-converting enzyme inhibitors implicated in oral mucosal lichenoid reactions. Oral Surg Oral Med Oral Pathol 1989; 67:41–4PubMedCrossRef

22.

Lakshmi C, Srinivas CR, Ramachandran B, et al. Perforating lichenoid reaction to amlodipine. Indian J Dermatol 2008; 53(2): 98–9PubMedCrossRef

23.

Halevy S, Shai A. Lichenoid drug eruptions. J Am Acad Dermatol 1993; 29: 249–55PubMedCrossRef

24.

Clayton R, Chaudhry S, Ali I, et al. Mucosal (oral and vulval) lichen planus in women: are angiotensin-converting enzyme inhibitors protective, and beta-blockers and non-steroidal anti-inflammatory drugs associated with the condition? Clin Exp Dermatol 2009; 35: 384–7PubMedCrossRef

25.

Habbab KM, Moles DR, Porter SR. Potential oral manifestations of cardiovascular drugs. Oral Dis 2010; 16: 769–73PubMedCrossRef

26.

Ellgehausen P, Elsner P, Burg G. Drug-induced lichen planus. Clin Dermatol 1998; 19: 325–32CrossRef

27.

Ramdial PK, Naidoo DK. Drug-induced cutaneous pathology. J Clin Pathol 2009; 62: 493–504PubMedCrossRef

28.

Justiniano H, Berlingeri-Ramos AC, Sanchez JL. Pattern analysis of drug-iduced skin diseases. Am J Dermatopathol 2008; 30: 352–69PubMedCrossRef

29.

Crowson NA, Magro Mihm M. Interface dermatitis. Arch Pathol Lab Med 2008; 132: 652–65PubMed

30.

West AJ, Berger TG, LeBoit PE. A comparative histopathologic study of photodistributed and nonphotodistributed lichenoid drug eruptions. J Am Acad Dermatol 1990; 23: 689–93PubMedCrossRef

31.

Lodi G, Scully Carrozzo M. Current controversies in oral lichen planus: report of an international consensus meeting. Part 1. Viral infections and etio-pathogenesis. Oral Surg Oral Med Oral Pathol Radiol Endod 2005; 100: 40–51CrossRef

32.

Shiohara T, Mizukawa Y. The immunological tissue reaction. Autoimmun Rev 2005; 4: 236–41PubMedCrossRef

33.

Sontheimer RD. Lichenoid tissue reaction/interface dermatitis: clinical and histological perspectives. J Invest Dermatol 2009; 129: 1088–99PubMedCrossRef

34.

Chen J, Hoffman BB, Isseroff RR. Adrenergic receptor activation inhibits keratinocyte migration via a cyclic adenosine monophosphate-independent mechanism. J Invest Dermatol 2002; 119: 1261–8PubMedCrossRef

35.

Manni M, Maestroni GJ. Sympathetic nervous modulation of the skin innate and adaptive immune response to peptidoglycan but not lipopolysaccharide: involvement of beta-adrenoceptors and relevance in inflammatory diseases. Brain Behav Immun 2008; 22(1): 80–8PubMedCrossRef

36.

Sivamani RK, Lam ST, Isseroff RR. Beta adrenergic receptors in keratinocytes. Dermatol Clin 2007; 25(4): 643–53PubMedCrossRef

37.

Steinkraus V, Steinfath M, Stöve L. Beta-adrenergic receptors in psoriasis: evidence for down-regulation in lesional skin. Arch Dermatol Res 1993; 285: 300–4PubMedCrossRef

38.

Schallreuter KU, Wood JM, Pittelkow MR, et al. Increased in vitro expression of beta 2-adrenoceptors in differentiating lesional keratinocytes of vitiligo patients. Arch Dermatol Res 1993; 285(4): 216–20PubMedCrossRef

39.

Gold MH, Holy AK, Roenigk HH. Beta-blocking drugs and psoriasis: a review of cutaneous side effects and retrospective analysis of their effects on psoriasis. J Am Acad Dermatol 1988; 19(5): 837–41PubMedCrossRef

40.

Steinkraus V, Mak JC, Pichmeirer U. Autoradiographic mapping of beta-adrenoceptors in human skin. Arch Dermatol Res 1996; 288: 549–53PubMedCrossRef

Title: Lichen Planus-Like Drug Eruptions Due to β-Blockers
A Case Report and Literature Review
Authors: Dr Chris Fessa
Penny Lim
Steve Kossard
Shawn Richards
Pablo Fernandez Peñas
Publication date: 01-12-2012
Publisher: Springer International Publishing
Published in: American Journal of Clinical Dermatology / Issue 6/2012
Print ISSN: 1175-0561
Electronic ISSN: 1179-1888
DOI: https://doi.org/10.2165/11634590-000000000-00000

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Lichen Planus-Like Drug Eruptions Due to β-Blockers

A Case Report and Literature Review

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 6/2012

Harnessing the Power of Crowds

Comparative Efficacy of Biologics in Psoriasis

Erratum to Efficacy and safety of calcipotriene 0.005% foam for the treatment of plaque-type psoriasis

Acknowledgment

Nail Psoriasis

A Review of Pediatric Vasculitis with a Focus on Juvenile Polyarteritis Nodosa